Soleno Therapeutics to Participate in Upcoming September Conferences

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:

Cantor Global Healthcare Conference
Presentation Date: Wednesday, September 3, 2025 at 1:00 PM ET
Presentation Format: Fireside Chat
Webcast: Here

Wells Fargo Healthcare Conference
Presentation Date: Thursday, September 4, 2025 at 1:30 PM ET
Presentation Format: Fireside Chat
Webcast: Here

H.C. Wainwright 27 th Annual Global Investment Conference
Presentation Date: Monday, September 8, 2025 at 4:00 PM ET
Presentation Format: Fireside Chat

Baird Global Healthcare Conference
Presentation Date: Tuesday, September 9, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat

Bernstein 2 nd Annual Healthcare Forum
Presentation Date: Thursday, September 25, 2025 at 9:40 AM ET
Presentation Format: Fireside Chat

Replays of the Cantor and Wells Fargo events will be available in the Investors section on the Company's website at www.soleno.life .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company's first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life .

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SLNO
The Conversation (0)
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...
Satellos Bioscience Inc.

Satellos Bioscience Inc.

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this... Keep Reading...
Vaxcyte Inc.

Vaxcyte Inc.

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Keep Reading...

Interactive Chart

Latest Press Releases

Related News